# Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)

> **NCT04460248** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** Zanubrutinib, Lenalidomide and Rituximab (ZR2)

## Key facts

- **NCT ID:** NCT04460248
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-08-26
- **Primary completion:** 2022-02-16
- **Final completion:** 2025-12-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04460248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04460248, "Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04460248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*